Optimizing the Electronic Properties of Photoactive Anticancer Oxypyridine-Bridged Dirhodium(II,II) Complexes

2-Aryl-1H-imidazo[4,5-f][1,10]phenanthroline-Based Binuclear Ru(II)/Ir(III)/Re(I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents

A series of novel Ru(II)/Ir(III)/Re(I)-based organometallic complexes [Ru2L1, Ru2L2, Ir2L1, Ir2L2, Re2L1, and Re2L2] have been synthesized to assess their potency and selectivity against multiple cancer cells A549, HCT-116, and HCT-116 colon CSCs. The cytotoxic screening of the synthesized complexes has revealed that complex Ru2L1 and Ir2L2 are two proficient complexes among all, but Ru2L1 is the most potent complex. A significant binding constant value was observed for DNA and BSA in all complexes. Significant lipophilic properties allow them to penetrate cancer cell membranes, and substantial quantum yield (ϕf) values support bioimaging potential. Again, these complexes are particular for mitochondrial localization and produce a profuse amount of ROS to damage the mitochondrial DNA and then G1 phase cell-cycle arrest. Protein expression analysis unveiled that pro-apoptotic Bax protein overexpressed in Ru2L1-treated cells, whereas antiapoptotic Bcl-2 protein was expressed twofold in Ir2L2-treated cells, which correlated with autophagy reticence.

A detailed density functional theory exploration of the photodissociation mechanism of ruthenium complexes for photoactivated chemotherapy

Polypyridyl Ru(II) complexes have attracted much attention due to their potential as light-activatable anticancer agents in photoactivated chemotherapy (PACT). The action of ruthenium-based PACT compounds relies on the breaking of a coordination bond between the metal center and an organic ligand via a photosubstitution reaction. Here, a detailed computational investigation of the photophysical properties of a novel trisheteroleptic ruthenium complex, [Ru(dpp)(bpy)(mtmp)]2+ (dpp = 4,7-diphenyl-1,10-phenanthroline, bpy = 2,2'-bipyridine and mtmp = 2-methylthiomethylpyridine), has been carried out by means of DFT and its time-dependent extension. All the aspects of the mechanism by which, upon light irradiation, the mtmp protecting group is released and the corresponding aquated complex, able to bind to DNA inducing cell death, is formed have been explored in detail. All the involved singlet and triplet states have been fully described, providing the calculation of the corresponding energy barriers. The involvement of solvent molecules in photosubstitution and the role played by pyridyl-thioether chelates as caging groups have been elucidated.

Luminescent 11-{Naphthalen-1-yl}dipyrido[3,2-a:2',3'-c]phenazine-Based Ru(II)/Ir(III)/Re(I) Complexes for HCT-116 Colorectal Cancer Stem Cell Therapy

Due to a number of unpleasant considerations, marketed drugs have steadily lost their importance in the treatment of cancer. In order to find a viable cancer cell diagnostic agent, we therefore focused on metal complexes that displayed target adequacy, permeability to cancer cells, high standard water solubility, cytoselectivity, and luminescent behavior. In this aspect, luminescent 11-{naphthalen-1-yl} dipyrido [3,2-a:2',3'-c] phenazine based Ru(II)/Ir(III)/Re(I) complexes have been prepared for HCT-116 colorectal cancer stem cell therapy. Our study successfully established the possible cytotoxicity of IrL complex at different doses on HCT-116 colorectal cancer stem cells (CRCSCs). Additionally, an immunochemistry analysis of the complex IrL showed that the molecule was subcellularly localized in the nucleus and other regions of the cytoplasm, where it caused nuclear DNA damage and mitochondrial dysfunction. The level of BAX and Bcl-2 was further quantified by qRT-PCR. The expression of proapoptotic BAX showed increased expression in the complex IrL-treated cell compared to the control, indicating the potential of complex IrL for apoptotic induction. Upon further validation, complex IrL was developed as an inhibitor of autophagy for the eradication of cancer stem cells.

Structure-property relationships of photofunctional diiridium(II) complexes with tetracationic charge and an unsupported Ir-Ir bond

In contrast to the extensively studied dirhodium(II) complexes and iridium(III) complexes, neutral or dicationic dinuclear iridium(II) complexes with an unsupported ligand are underdeveloped. Here, a series of tetracationic dinuclear iridium(II) complexes, featuring the unsupported Ir(II)-Ir(II) single bond with long bond distances (2.8942(4)-2.9731(4) Å), are synthesized and structurally characterized. Interestingly, compared to the previous unsupported neutral or dicationic diiridium(II) complexes, our DFT and high-level DLPNO-CCSD(T) results found the largest binding energy in these tetracationic complexes even with the long Ir(II)-Ir(II) bond. Our study further reveals that London dispersion interactions enhance the stability cooperatively and significantly to overcome the strong electrostatic repulsion between two half dicationic metal fragments. This class of complexes also exhibit photoluminescence in solution and solid states, which, to our knowledge, represents the first example of this unsupported dinuclear iridium(II) system. In addition, their photoreactivity involving the generation of iridium(II) radical monomer from homolytic cleavage was also explored. The experimental results of photophysical and photochemical behaviours were also correlated with computational studies.

[Ru(η6-p-cymene)(N^O 8-hydroxyquinoline)(PTA)] complexes as rising stars in medicinal chemistry: synthesis, properties, biomolecular interactions, in vitro anti-tumor activity toward human brain carcinomas, and in vivo biodistribution and toxicity in a zebrafish model

Herein, we have introduced a class of half-sandwich [Ru(η⁶-p-cymene)(N^O 8-hydroxyquinoline)(PTA)] complexes for brain cancer therapy. Among all the complexes, [RuL3PTA] and [RuL4PTA] exhibited excellent cytotoxicity profiles against T98G, LN229, and U87MG cancer cells. Notably, the antiproliferative activities of the relevant complexes were also supported by neurosphere, DNA intercalation, agarose gel electrophoresis, and time-dependent ROS detection assay studies. Detailed molecular assays were obtained via real-time reverse transcription (RT)-polymerase chain reaction (PCR) experiments. Moreover, the in vivo biodistribution of the [RuL4PTA] complex in different organs and the morphological patterns of zebrafish embryos due to toxic effects have been evaluated.

Alkylgold(III) Complexes Undergo Unprecedented Photo-Induced β-Hydride Elimination and Reduction for Targeted Cancer Therapy

Spatiotemporally controllable activation of prodrugs within tumors is highly desirable for cancer therapy to minimize toxic side effects. Herein we report that stable alkylgold(III) complexes can undergo unprecedented photo-induced β-hydride elimination, releasing alkyl ligands and forming gold(III)-hydride intermediates that could be quickly converted into bioactive [Au^III -S] adducts; meanwhile, the remaining alkylgold(III) complexes can photo-catalytically reduce [Au^III -S] into more bioactive Au^I species. Such photo-reactivities make it possible to functionalize gold complexes on the auxiliary alkyl ligands without attenuating the metal-biomacromolecule interactions. As a result, the gold(III) complexes containing glucose-functionalized alkyl ligands displayed efficient and tumor-selective uptake; notably, after one- or two-photon activation, the complexes exhibited high thioredoxin reductase (TrxR) inhibition, potent cytotoxicity, and strong antiangiogenesis and antitumor activities in vivo.

Iridium(III)-Cp*-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol analogues as hypoxia active, GSH-resistant cancer cytoselective and mitochondria-targeting cancer stem cell therapeutic agents

Herein, we have introduced a series of iridium(III)-Cp*-(imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol complexes via a convenient synthetic methodology, which act as hypoxia active and glutathione-resistant anticancer metallotherapeutics. The [Ir^III(Cp*)(L5)(Cl)](PF₆) (IrL5) complex exhibited the best cytoselectivity, GSH resistance and hypoxia effectivity in HeLa and Caco-2 cells among the synthesized complexes. IrL5 also exhibited highly cytotoxic effects on the HCT-116 CSC cell line. This complex was localized in the mitochondria and subsequent mitochondrial dysfunction was observed via MMP alteration and ROS generation on colorectal cancer stem cells. Cell cycle analysis also established the potential of this complex in mediating G2/M phase cell cycle arrest.

BODIPY-linked cis-dichlorido zinc(ii) conjugates: the strategic design of organelle-specific next-generation theranostic photosensitizers

Cis-dichlorido Zn(ii)–BODIPY-based smart theranostic photosensitizers, as alternatives to Zn-porphyrins/phthalocyanines, show mitochondrion-targeted and imaging guided type-II photodynamic therapeutic activity.

Synthetic Strategies for Trapping the Elusive trans-Dirhodium(II,II) Formamidinate Isomer: Effects of Cis versus Trans Geometry on the Photophysical Properties

The cis- and trans-dirhodium(II,II) complexes cis-[Rh₂(μ-DTolF)₂(μ-np)(MeCN)₄][BF₄]₂ (1; DTolF = N,N'-di-p-tolylformamidinate and np = 1,8-naphthyridine), cis- and trans-[Rh₂(μ-DTolF)₂(μ-qxnp)(MeCN)₃][BF₄]₂ [2 and 3, respectively, where qxnp = 2-(1,8-naphthyridin-2-yl)quinoxaline], and trans-[Rh₂(μ-DTolF)₂(μ-qxnp)₂][BF₄]₂ (4) were synthesized and characterized. A new synthetic methodology was developed that consists of the sequential addition of π-accepting axially blocking ligands to favor formation of the first example of a bis-substituted formamidinate-bearing trans product. Isolation of the intermediates 2 and 3 provides insight into the mechanistic requirements for obtaining 4 and the cis analogue, cis-[Rh₂(μ-DTolF)₂(μ-qxnp)₂][BF₄]₂ (5). Density functional theory calculations provide support for the synthetic mechanism and proposed intermediates. The metal/ligand-to-ligand charge-transfer (ML-LCT) absorption maximum of the trans complex 4 at 832 nm is red-shifted by 1173 cm^-1 and exhibits shorter lifetimes of the ¹ML-LCT and ³ML-LCT excited states, 3 ps and 0.40 ns, respectively, compared to those of the cis analogue 5. The shorter excited-state lifetimes of 4 are attributed to the longer Rh-Rh bond of 2.4942(8) Å relative to that in 5, 2.4498(2) Å. A longer metal-metal bond reflects a decreased overlap of the Rh atoms, which leads to more accessible metal-centered excited states for radiationless deactivation. The ³ML-LCT excited states of 4 and 5 undergo reversible bimolecular charge transfer with the electron donor p-phenylenediamine when irradiated with low-energy light. These results indicate that trans isomers are a source of unexplored tunability for potential p-type semiconductor applications and, given their distinct geometric arrangement, constitute useful building blocks for supramolecular architectures with potentially interesting photophysical properties.

New Designs for Phototherapeutic Transition Metal Complexes

In this Minireview, we highlight recent advances in the design of transition metal complexes for photodynamic therapy (PDT) and photoactivated chemotherapy (PACT), and discuss the challenges and opportunities for the translation of such agents into clinical use. New designs for light-activated transition metal complexes offer photoactivatable prodrugs with novel targeted mechanisms of action. Light irradiation can provide spatial and temporal control of drug activation, increasing selectivity and reducing side-effects. The photophysical and photochemical properties of transition metal complexes can be controlled by the appropriate choice of the metal, its oxidation state, the number and types of ligands, and the coordination geometry.

Hypoxia efficient and glutathione-resistant cytoselective ruthenium(ii)-p-cymene-arylimidazophenanthroline complexes: biomolecular interaction and live cell imaging

A series of ruthenium(ii)–arene-2-arylimidazophenanthroline based DNA targeting, cytoselective, hypoxia efficient and glutathione-resistant luminescent anticancer drugs have been developed which are also represented as HeLa cell imaging probes.

Rhodium at the chemistry-biology interface

As a rare element with no known natural biological function, rhodium has a limited history in biological chemistry and chemical biology. However, rhodium complexes have unique structure and reactivity attributes, and chemists have increasingly used these attributes to probe and perturb living systems. This brief review focuses on recent advances in the use of rhodium complexes in biological contexts, including medicinal chemistry, protein science, and chemical biology. In particular, we highlight both structure- and reactivity-driven approaches to biological probes and discuss how coordination environment affects molecular properties in a biological environment.

Why develop photoactivated chemotherapy?

Photoactivated chemotherapy is an approach where a biologically active compound is protected against interaction with the cell environment by a light-cleavable protecting group, and unprotected by light irradiation. As such, PACT represents a major scientific opportunity for developing new bioactive inorganic compounds. However, the societal impact of this approach will only take off if the PACT field is used to address real societal challenges, i.e., therapeutic questions that make sense in a clinical context, rather than purely chemical questions. In particular, I advocate here that the field has become mature enough to switch from a compound-based approach, where a particular cancer model is chosen only to demonstrate the utility of a compound, to a disease-based approach, where the question of which disease to cure comes first: which PACT compound should I make to solve that particular clinical problem? The advantages and disadvantages of PACT vs. other phototherapeutic techniques are discussed, and a roadmap towards real clinical applications of PACT is drawn.

Coordination capacity of cytosine, adenine and derivatives towards open-paddlewheel diruthenium compounds

[Ru₂Cl₂(DPhF)₃] (DPhF = diphenylformamidinate) links preferentially to the junctions of RNA (ribonucleic acid) structures, although the bonding mode is not known. In order to clarify this question the reactions between [Ru₂Cl₂(DPhF)₃] and cytosine (Hcyto), cytidine (Hcyti), cytidine 2',3'-cyclic monophosphate sodium salt (NacCMP), adenine (Hade), adenosine (Haden) and adenosine 3',5'-cyclic monophosphate (HcAMP) have been carried out. In the resultant complexes, cyto (cytosinate), cyti (cytidinate), cCMP (cytidine 2',3'-cyclic monophosphate monoanion), ade (adeninate), aden (adenosinate) and cAMP (deprotonated adenosine 3',5'-cyclic monophosphate) are bonded to the diruthenium unit as N,N'-bridging ligands, as confirmed by the solution of the crystal structures of [RuCl(DPhF)₃(cyto)] and [RuCl(DPhF)₃(ade)] by X-ray diffraction. The axial positions of the diruthenium species are still available for additional interactions with other residues that could explain its preference towards RNA junctions.

Controlling with light the interaction between trans-tetrapyridyl ruthenium complexes and an oligonucleotide

Three new trans-ruthenium(ii) complexes coordinated to tetrapyridyl ligands, namely [Ru(bapbpy)(dmso)Cl]Cl ([2]Cl), [Ru(bapbpy)(Hmte)₂](PF₆)₂ ([3](PF₆)₂), and [Ru(biqbpy)(Hmte)₂](PF₆)₂ ([4](PF₆)₂), were prepared as analogues of [Ru(biqbpy)(dmso)Cl]Cl ([1]Cl), a recently described photoactivated chemotherapy agent. The new complexes were characterized, and their crystal structures showed the distorted coordination octahedron typical of this family of complexes. Their photoreactivity in solution was analyzed by spectrophotometry and mass spectrometry, which showed that the sulfur ligand was substituted upon blue light irradiation. The binding of the ruthenium complexes to a reference single-stranded oligonucleotide (s(^5'CTACGGTTTCAC^3')) was explored both in the dark and under light irradiation by gel electrophoresis and high-resolution mass spectrometry. While adduct formation in the dark was negligible for the four complexes, light irradiation led to the formation of adducts with one or two ruthenium centers per oligonucleotide. The absence of interactions in the dark and the presence of complex-oligonucleotide adducts demonstrate that visible light controls the interaction of these ruthenium complexes with nucleic acids.

Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents

Cyclometalated iridium(iii) complexes bearing different numbers of fluorine atoms were developed to induce apoptosis via mitochondrial pathways and demonstrated much better anticancer activities than the widely used clinical chemotherapeutic agent cisplatin.

Combatting AMR: photoactivatable ruthenium(ii)-isoniazid complex exhibits rapid selective antimycobacterial activity

The novel photoactive ruthenium(ii) complex cis-[Ru(bpy)2(INH)2][PF6]2 (1·2PF6, INH = isoniazid) was designed to incorporate the anti-tuberculosis drug, isoniazid, that could be released from the Ru(ii) cage by photoactivation with visible light. In aqueous solution, 1 rapidly released two equivalents of isoniazid and formed the photoproduct cis-[Ru(bpy)2(H2O)2]2+ upon irradiation with 465 nm blue light. We screened for activity against bacteria containing the three major classes of cell envelope: Gram-positive Bacillus subtilis, Gram-negative Escherichia coli, and Mycobacterium smegmatis in vitro using blue and multi-colored LED multi-well arrays. Complex 1 is inactive in the dark, but when photoactivated is 5.5× more potent towards M. smegmatis compared to the clinical drug isoniazid alone. Complementary pump-probe spectroscopy measurements along with density functional theory calculations reveal that the mono-aqua product is formed in <500 ps, likely facilitated by a 3MC state. Importantly, complex 1 is highly selective in killing mycobacteria versus normal human cells, towards which it is relatively non-toxic. This work suggests that photoactivatable prodrugs such as 1 are potentially powerful new agents in combatting the global problem of antibiotic resistance.

Os2 -Os4 Switch Controls DNA Knotting and Anticancer Activity

Dinuclear trihydroxido‐bridged osmium–arene complexes are inert and biologically inactive, but we show here that linking dihydroxido‐bridged Os^II–arene fragments by a bridging di‐imine to form a metallacycle framework results in strong antiproliferative activity towards cancer cells and distinctive knotting of DNA. The shortened spacer length reduces biological activity and stability in solution towards decomposition to biologically inactive dimers. Significant differences in behavior toward plasmid DNA condensation are correlated with biological activity.

Filling a Gap: Electrochemical Property Comparison of the Completed Compound Series [Mo2(DArF)n(O2C-Fc)4-n] (DArF = N,N'-Diarylformamidinate; O2C-Fc = Ferrocenecarboxylate)

The reaction of cis-[Mo2(O2C-Fc)2(NCCH3)4][BF4]2 (cis-1) with two electronically different N,N'-diarylformamidinate (DArF) ligands (DArF = N,N'-bis(p-trifluoromethylphenyl)formamidinate (DTfmpF), N,N'-bis(p-anisyl)formamidinate (DAniF)) results in the isolation of the tris- and monosubstituted complexes [Mo2(DTfmpF)3(O2C-Fc)] (2a) and [Mo2(DAniF)(O2C-Fc)3] (2b). These complexes complete the series of [Mo2(DArF)n(O2C-Fc)4-n] (n = 4-0) type compounds, thus allowing for a comprehensive study. On the basis of the oxidation potential E1/2([Mo2](4+)/[Mo2](5+)) of all Mo2 complexes, ligand basicity is found to decrease in the order DAniF(-) > DTfmpF(-) > Fc-CO2(-) ≫ CH3CN. In addition, no direct electronic interaction between the trans-positioned Fc units in complex 2b is detected, which is attributed to the full overlap of all Fc oxidation processes. Furthermore, the low-energy absorption bands of compounds 2a,b are located at different positions in their respective UV-vis spectra.

Fine control on the photochemical and photobiological properties of Ru(II) arene complexes

A series of six Ru(arene) complexes, [(η(6)-p-cymene)Ru(dpb)(py-R)](2+) (1-6, dpb = 2,3-bis(2-pyridyl)benzoquinoxaline, py-R = 4-substituted pyridine, R = N(CH3)2, NH2, OCH3, H, COOCH3 and NO2), were synthesized and their photochemical and photobiological properties were compared in detail. The electron push/pull character of the R groups has a significant impact on both ligand photodissociation and (1)O2 generation of the complexes. The photoinduced DNA covalent binding capabilities increase from 1 to 6 under both aerobic and anaerobic conditions, and DNA photocleavage occurs simultaneously in aerobic environments. 4 has the most potent phototoxicity against human lung carcinoma A549 cells among the examined complexes. The substituent effect may be ascribed to the influences of the R groups on the energy levels of (3)MC and (3)MLCT states as well as the energy gaps between (3)MC, (3)MLCT and dpb-based (3)IL states. Similar chemical modification on bidentate and arene ligands or other sites of the pyridine ligand may lead to more efficient agents with PDT and/or PACT activities.

A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin

A photoactivatable platinum(IV) complex, trans,trans,trans-[Pt(N3 )2 (OH)(succ)(py)2 ] (succ=succinylate, py=pyridine), has been conjugated to guanidinoneomycin to study the effect of this guanidinum-rich compound on the photoactivation, intracellular accumulation and phototoxicity of the pro-drug. Surprisingly, trifluoroacetic acid treatment causes the replacement of an azido ligand and the axial hydroxide ligand by trifluoroacetate, as shown by NMR spectroscopy, MS and X-ray crystallography. Photoactivation of the platinum-guanidinoneomycin conjugate in the presence of 5'-guanosine monophosphate (5'-GMP) led to the formation of trans-[Pt(N3 )(py)2 (5'-GMP)](+) , as does the parent platinum(IV) complex. Binding of the platinum(II) photoproduct {PtN3 (py)2 }(+) to guanine nucleobases in a short single-stranded oligonucleotide was also observed. Finally, cellular uptake studies showed that guanidinoneomycin conjugation improved the intracellular accumulation of the platinum(IV) pro-drug in two cancer cell lines, particularly in SK-MEL-28 cells. Notably, the higher phototoxicity of the conjugate in SK-MEL-28 cells than in DU-145 cells suggests a degree of selectivity towards the malignant melanoma cell line.